Better Pharma Dividend Stock: Novartis vs. Merck [Globe and Mail, The (Toronto, Canada)]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Globe and Mail, The
Both are attractive dividend stocks, but one has the edge right now, partly because of its valuation. The pharmaceutical industry is a good place to look for solid dividend stocks. Since they offer lifesaving therapies, drugmakers generally see consistent demand for their products, even amid severe economic challenges. That allows them to generate consistent financial results and grow their dividends even during tough times. However, not all pharma dividend stocks are equally worth investing in. Consider Merck (NYSE: MRK) and Novartis (NYSE: NVS) , two of the largest in the game. They have a lot in common: deep product lineups, strong pipelines, and both have beaten the S&P 500 over the past 12 months (as of writing). But which one of these is the better dividend stock? Let's find out. Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critic
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Roche's DAC investment; Big Pharma's lavish CEO bumps [Yahoo! Finance]Yahoo! Finance
- Better Pharma Dividend Stock: Novartis vs. Merck [Yahoo! Finance]Yahoo! Finance
- UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview [Yahoo! Finance]Yahoo! Finance
- European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonBusiness Wire
- Harbour BioMed Appoints Dr. Adam Zong as President [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website